Heart rate variability in male patients with metabolic syndrome
https://doi.org/10.14341/2072-0351-3591
Abstract
Aim.
To study the heart rate variability via 24-hours ECG monitoring in male patients with metabolic syndrome (MS) and no signs of ischemic heart disease (IHD).
Materials and Methods.
131 males aged 29 to 60 years with no evidence for IHD were enrolled for this study and underwent 24-hoursECG monitoring procedure.
Results.
We determined that MS in males is associated with dysautonomia, accompanied by decrease in sympathetic heart stimulation (specifically, in LF and VLF parameters) and left ventricular diastolic abnormalities that correlate with abdominal obesity.
Conclusion.
MS in males is associated with dysautonomia, accompanied by decrease in sympathetic heart stimulation (specifically, in LF and VLF parameters) and left ventricular diastolic abnormalities that correlate with abdominal obesity.
To study the heart rate variability via 24-hours ECG monitoring in male patients with metabolic syndrome (MS) and no signs of ischemic heart disease (IHD).
Materials and Methods.
131 males aged 29 to 60 years with no evidence for IHD were enrolled for this study and underwent 24-hoursECG monitoring procedure.
Results.
We determined that MS in males is associated with dysautonomia, accompanied by decrease in sympathetic heart stimulation (specifically, in LF and VLF parameters) and left ventricular diastolic abnormalities that correlate with abdominal obesity.
Conclusion.
MS in males is associated with dysautonomia, accompanied by decrease in sympathetic heart stimulation (specifically, in LF and VLF parameters) and left ventricular diastolic abnormalities that correlate with abdominal obesity.
About the Authors
Andrey Evgen'evich Kratnov
Yaroslavl State Medical Academy, Yaroslavl
A V Yakimova
Yaroslavl State Medical Academy, Yaroslavl
E E Silkina
Yaroslavl Railroad Hospital, Yaroslavl
References
1. Шестакова МВ. Метаболический синдром – реальная угроза здоровью населения всех стран мира. Медицинский вестник. 2009;(484):9–10.
2. Явелов ИС. Внезапная сердечная смерть при метаболическом синдроме. Трудный пациент. 2012; 10(6):34–39.
3. Bigger JT, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rott- man JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation. 1992 Jan;85(1):164–171.
4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr;International Diabetes Federation Task Force on Epidemiol- ogy and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Inter- national Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640–1645. DOI: 10.1161/CIRCULA- TIONAHA.109.192644.
5. Мареев ВЮ, Агеев ФТ, Арутюнов ГП, Коротеев АВ, Ревиш- вили АШ. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная Недостаточность. 2007; 8(1):4–41.
6. Явелов ИС. Вариабельность ритма сердца при сердечно-сосудистых заболеваниях: взгляд клинициста. Сердце: журнал для практикующих врачей. 2006;1(25):18–23.
7. Malik M, Camm J. Components of heart rate variability – what they really mean and what we really measure. Am J Cardiol. 1993 Oct 1;72(11):821–822.
8. Malliani A, Montano N, Pagani M. Physiological background of heart rate variability. Cardiac Electrophysiology Review. 1997;(3):345–348.
9. Мамедов МН, Шарвадзе ГГ, Поддубская ЕА, Дидигова РТ. Проблемы мужского здоровья с точки зрения кардиолога. Кардиология. 2011; 51(11):91–96.
10. Ощепкова ЕВ. Смертность населения от сердечно-сосудистых заболеваний в Российской Федерации в 2001–2006 гг. и пути по ее снижению. Кардиология. 2009; 49(2):67–72.
11. Оганов Р, Мамедов М, Колтунов И. Метаболический синдром: путь от научной концепции до клинического диагноза. Врач. 2007; (3):3–7.
12. Чазова ИЕ, Мычка ВБ. Метаболический синдром, сахарный диабет 2 типа и артериальная гипертензия. Сердце: журнал для практикующих врачей. 2003;2(9):102–104.
13. Дедов ИИ, Александров АА. Диабетическое сердце: Causa Magna. Сердце: журнал для практикующих врачей. 2004; 3(1):5–8.
14. Stevens MJ, Raffel DM, Allman KC, Dayanikil F, Ficaro E, Sandford Т, Wieland DM, Pfeifer MA, Schwaiger M. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation. 1998 Sep 8;98(10):961–968.
15. Дедов ИИ, Мельниченко ГА, Фадеев ВВ. Эндокринология. М; 2000. С. 494–500.
16. Кратнов АЕ, Демьянкова ЮО, Шорманова ЛО. Случай дилатационной кардиомиопатии у больного с метаболическим синдромом. Трудный пациент. 2011; 9(6):20–23.
Review
For citations:
Kratnov A.E., Yakimova A.V., Silkina E.E. Heart rate variability in male patients with metabolic syndrome. Diabetes mellitus. 2013;16(1):15-18. (In Russ.) https://doi.org/10.14341/2072-0351-3591
Views:
804
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
